American Journal of Transplantation· 2013Q1
Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury
- 263citations
- Q1SCImago
- 2013year
Short summary
Urinary CXCL9 mRNA and protein levels effectively diagnose acute rejection (AR) in kidney transplant recipients, with protein showing higher accuracy (OR 3.40, PPV 67.6%, NPV 92%). Low CXCL9 protein post-transplant predicts a low risk of future AR or declining kidney function.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine